$BHC and there we have it; Papa made Bausch Pharma/Remainco less attractive today "Bausch Health Cos. Inc. (BHC) today raised its leverage target for Bausch Pharma (the remaining entity after the company's proposed spin of its eye-care business), to ~6.5x-6.7x at the time of the proposed spin-off, roughly 1x higher than the previous target of mid-5x. -- S&P Global Ratings is affirming the 'B+' issuer credit rating on BHC and revising our outlook to negative from stable".
1 Like